A phase 1 human clinical trial of a compound developed by Paul Donnelly, School of Chemistry and Kevin Barnham (Florey Institute of Neuroscience and Mental Health) whilst at the Bio21 Molecular Science and Biotechnology Institute and Anthony White, University of Melbourne and is showing promise in alleviating the symptoms of Parkinson’s disease.